Under the terms of the agreement, Eleva secures production capacity at 3PBIOVIAN for the clinical-grade material needed to advance its current pipeline programs into mid- to late-stage clinical development. This covers Factor H (CPV-104), a novel complement modulator currently being developed in C3 Glomerulopathy (C3G) and dry age-related macular degeneration (dry AMD).

Related article

Navigating the Financial Landscape: Merger

Combining the strengths of two companies is a way to position against competitors and also become more resilient to a fluctuating financial market.


Additionally, 3PBIOVIAN acquires a non-exclusive license to Eleva’s expression system. As a result of the alliance, Eleva essentially triples its offering of GMP production capacity for programs based on its technology platform.

“We are delighted that Eleva has selected us as a partner for the manufacturing of clinical material for their current pipeline programs, including their novel complement regulator Factor H (CPV-104), which could provide patients with a much-needed new therapeutic option. Access to Eleva’s expression system also supports our commitment to meet the evolving needs of biopharmaceutical developers by continuously expanding our capabilities. Moss-based expression adds a valuable new dimension to our established high-quality offerings in biologics manufacturing,” says Dámaso Molero Sánchez, Group CEO at 3PBIOVIAN. “